Ardelyx Stock Gets Increased EPS Forecast from HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at HC Wainwright increased their FY2026 earnings estimates for shares of Ardelyx in a report issued on Wednesday, November 4th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will post earnings of ($0.18) per share for the year, up from their previous forecast of ($0.26). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ardelyx’s Q4 2026 earnings at $0.04 EPS, FY2027 earnings at $0.06 EPS, FY2029 earnings at $1.18 EPS and FY2030 earnings at $1.58 EPS.

Other analysts have also issued research reports about the company. Citigroup decreased their price target on Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Wedbush reaffirmed an “outperform” rating and set a $9.00 price objective on shares of Ardelyx in a research note on Tuesday, August 18th. BTIG Research cut their price objective on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Piper Sandler reduced their target price on shares of Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ardelyx in a research note on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Ardelyx presently has an average rating of “Moderate Buy” and a consensus price target of $13.90.

Ardelyx Stock Performance

NASDAQ ARDX opened at $2.99 on Friday. The company has a debt-to-equity ratio of 1.54, a current ratio of 3.45 and a quick ratio of 3.15. The business’s 50 day moving average price is $3.37 and its 200-day moving average price is $5.26. Ardelyx has a fifty-two week low of $2.95 and a fifty-two week high of $8.40.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $120.88 million during the quarter, compared to the consensus estimate of $121.03 million. Ardelyx had a negative return on equity of 35.30% and a negative net margin of 11.85%. The company’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.08) EPS.

Insider Activity at Ardelyx

In other Ardelyx news, CEO Michael Raab sold 58,574 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $226,095.64. Following the completion of the sale, the chief executive officer directly owned 1,619,792 shares of the company’s stock, valued at $6,252,397.12. The trade was a 3.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James Brady sold 15,136 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $58,424.96. Following the completion of the transaction, the insider owned 245,930 shares in the company, valued at $949,289.80. This represents a 5.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 126,059 shares of company stock worth $486,588 over the last ninety days. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ardelyx

A number of institutional investors and hedge funds have recently bought and sold shares of ARDX. BlackRock Inc. bought a new position in shares of Ardelyx during the second quarter valued at approximately $119,874,000. Jupiter Topco LLC purchased a new position in Ardelyx during the second quarter valued at approximately $27,043,000. AIGH Capital Management LLC bought a new position in Ardelyx in the second quarter worth approximately $16,320,000. Bank of America Corp DE raised its stake in Ardelyx by 5.8% in the first quarter. Bank of America Corp DE now owns 2,336,994 shares of the biopharmaceutical company’s stock worth $13,999,000 after buying an additional 128,301 shares in the last quarter. Finally, Eversept Partners LP raised its stake in Ardelyx by 30.0% in the first quarter. Eversept Partners LP now owns 2,229,446 shares of the biopharmaceutical company’s stock worth $13,354,000 after buying an additional 514,317 shares in the last quarter. 58.92% of the stock is owned by institutional investors.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Ardelyx reported third-quarter EPS of $0.00, ahead of analysts’ expectation of a $0.02 loss. Product revenue was $125.5 million, while total revenue of $127.66 million came in slightly below estimates; revenue grew 21% year over year. The company maintained its 2026 IBSRELA revenue outlook of $350 million to $370 million. Ardelyx Q3 earnings
• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to $0.04 from $0.01 and its FY2026 estimate to a loss of $0.18 per share from a loss of $0.26. The firm kept its Buy rating and $13 price target. TD Cowen also reaffirmed its Buy rating. TD Cowen rating
• Neutral Sentiment: The company completed enrollment in its Phase 3 ACCEL trial of IBSRELA for adults with chronic idiopathic constipation, an operational milestone ahead of future trial updates. ACCEL trial enrollment
• Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027, FY2029 and FY2030, including a reduction for FY2029 to $1.18 from $1.56. The longer-term estimate revisions temper the improvement in its near-term outlook.
• Negative Sentiment: Multiple law firms publicized a securities class action against Ardelyx, with a November 16 lead-plaintiff deadline. The lawsuit alleges the company misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH; these claims are allegations, not established findings. Litigation adds uncertainty and reputational risk. Class action allegations

About Ardelyx

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.